Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma

被引：0
|
作者：
Albrecht, L. J. [1 ]
Dimitriou, F. [2 ]
Grover, P. [3 ]
Hassel, J. C. [4 ,5 ]
Erdmann, M. [6 ]
Forschner, A. [7 ]
Johnson, D. [8 ,9 ]
Livingstone, E. [1 ]
Roesch, A. [1 ,10 ]
Ugurel, S. [1 ]
Schulz, C. [4 ,5 ]
Berking, C. [6 ]
Menzies, A. M. [3 ,11 ,12 ]
Long, G. V. [11 ,12 ]
Dummer, R. [2 ]
Schadendorf, D. [1 ,10 ]
Zimmer, L. [1 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia
[4] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[6] Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany
[7] Univ Hosp Tuebingen, Dept Dermatol, Tubingen, Germany
[8] VUMC, Dept Med, Div Hematol & Oncol, Nashville, TN USA
[9] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA
[10] German Canc Consortium DKTK, Essen, Germany
[11] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, Australia
[12] Univ Sydney, Fac Med & Hlth, Sydney, Australia
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP023
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
    Ahmed, K. A.
    Abuodeh, Y. A.
    Echevarria, M. I.
    Arrington, J. A.
    Stallworth, D. G.
    Hogue, C.
    Naghavi, A. O.
    Kim, S.
    Kim, Y.
    Patel, B. G.
    Sarangkasiri, S.
    Johnstone, P. A. S.
    Sahebjam, S.
    Khushalani, N. I.
    Forsyth, P. A.
    Harrison, L. B.
    Yu, M.
    Etame, A. B.
    Caudell, J. J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (12) : 2288 - 2294
  • [32] The Effects of Brain Metastases in Melanoma Patients on anti-PD1 Antibody Therapy with Pembrolizumab
    Weichenthal, M.
    Mohr, P.
    Leiter-Stoeppke, U.
    Ugurel, S.
    Kaehler, K.
    Gutzmer, R.
    Pfoehler, C.
    Hassel, J. C.
    Nashan, D.
    Terheyden, P.
    Schell, B.
    Utikal, J. S.
    Kreuter, A.
    Haferkamp, S.
    Kaune, K.
    Berking, C.
    Debus, D.
    Ulrich, J.
    Dabrowski, E.
    Eigentler, T.
    Welzel, J.
    Herbst, R.
    Loquai, C.
    Meier, F.
    Schadendorf, D.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 5 - 6
  • [33] Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
    Taylor, Amelia M.
    McKeown, Janet
    Dimitriou, Florentia
    Jacques, Sarah K.
    Zimmer, Lisa
    Allayous, Clara
    Yeoh, Hui-Ling
    Haydon, Andrew
    Ressler, Julia M.
    Galea, Claire
    Woodford, Rachel
    Kahler, Katharina
    Hauschild, Axel
    Festino, Lucia
    Hoeller, Christoph
    Schwarze, Julia K.
    Neyns, Bart
    Wicky, Alexandre
    Michielin, Olivier
    Placzke, Joanna
    Rutkowski, Piotr
    Johnson, Douglas B.
    Lebbe, Celeste
    Dummer, Reinhard
    Ascierto, Paolo A.
    Lo, Serigne
    Long, Georgina V.
    Carlino, Matteo S.
    Menzies, Alexander M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [34] Stereotactic Body Radiation Therapy Plus Anti-PD1/IL8 Therapy for Advanced Solid Tumors
    Olson, A. C.
    Karapetyan, L.
    Gooding, W.
    Bao, R.
    Chmura, S. J.
    Luke, J. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E448 - E449
  • [35] Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.
    Colle, Elise
    Dalle, Stephane
    Mortier, Laurent
    Guillot, Bernard
    Dutriaux, Caroline
    Leccia, Marie Therese
    Dalac, Sophie
    Legoupil, Delphine
    De Quatrebarbes, Julie
    Montaudie, Henri
    Arnault, Jean-Philippe
    Brunet-Possenti, Florence
    Saiag, Philippe
    Momenzadeh, Mathieu
    Dreno, Brigitte
    Porcher, Raphael
    Oriano, Bastien
    Lebbe, Celeste
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] A PHASE II TRIAL OF NIVOLUMAB PLUS AXITINIB IN PATIENTS WITH ANTI-PD1 REFRACTORY ADVANCED MELANOMA
    Shaikh, Saba
    Zang, Yan
    Wang, Hong
    Yang, Xi
    Sander, Cindy
    Rose, Amy
    Davar, Diwakar
    Luke, Jason
    Zarour, Hassane
    Kirkwood, John
    Delgoffe, Greg
    Najjar, Yana
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A265 - A265
  • [37] A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma
    Joshi, Urvashi Mitbander
    Shaikh, Saba
    Zang, Yan
    Wang, Hong
    Sander, Cindy
    Rose, Amy
    Davar, Diwakar
    Luke, Jason J.
    Zarour, Hassane M.
    Kirkwood, John M.
    Delgoffe, Greg M.
    Najjar, Yana G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Patients with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors in first line therapy?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 : A9 - A12
  • [39] Management of melanoma recurrence following adjuvant anti-PD1 therapy
    Owen, C.
    Palmieri, D.
    Guminski, A.
    Carlino, M. S.
    Menzies, A. M.
    Long, G. V.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [40] Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature
    Dudda, Milena
    Mann, Caroline
    Heinz, Jaqueline
    Schmidgen, Isabel
    Weid, Florian
    Kuhn, M.
    Saloga, Joachim
    Grabbe, Stephan
    Loquai, Carmen
    [J]. MELANOMA RESEARCH, 2021, 31 (01) : 81 - 84
12345